Based on our newly-generated data, IL-4, IL-13 and their receptors IL-4Rα, IL-13Rα1, IL-13Rα2 may be reasonable therapeutic targets in DIPG due to differential overexpression on the cell surface of cancerous cells. Here, IL13RA2 is linked to diffuse intrinsic pontine glioma.